Savara Pharmaceuticals plans to expand its pipeline of orphan respiratory drugs by acquiring Serendex Pharmaceuticals, a provider of inhalation therapies for rare respiratory conditions.
Pursuant to the transaction, Savara Pharma will acquire all of Serendex Pharma’s assets to add up to two new programmes in its pipeline.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Xiangxue Pharmaceuticals has announced that it will acquire a 60% stake in a Guangzhou-based biotechnology company.
Xiangxue Pharmaceuticals plans to acquire the company through stake acquisition and in the form of cash or equity.
